Following on from information provided to NICE by the company in September 2022, the appraisal of Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1667
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 September 2023 | Discontinued. Following on from information provided to NICE by the company in September 2022, the appraisal of Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2022 | Suspended. As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]. For information, the company have announced that KEYNOTE-412 trial did not meet its primary endpoint in and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 20 May 2022 | Note added to the project documents |
| 16 July 2021 | Note added to the project documents |
| 19 February 2021 | Note added to the project documents |
| 16 December 2019 | In progress. Referred 25 March 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual